Details

Autor(en) / Beteiligte

• Jankovic, Marina Gazdic
• Stojkovic, Miodrag
• Bojic, Sanja
• Jovicic, Nemanja
• Kovacevic, Marina Miletic
• Ivosevic, Zeljko
• Juskovic, Aleksandar
• Kovacevic, Vojin
• Ljujic, Biljana

Titel

Scaling up human mesenchymal stem cell manufacturing using bioreactors for clinical uses

Ist Teil von

• Current research in translational medicine, 2023-04, Vol.71 (2), p.103393-103393, Article 103393

Ort / Verlag

France: Elsevier Masson SAS

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• •Human mesenchymal stem cells (hMSCs) are the most promising pharmaceutical multipotent stem cells.•Despite the vast potential, the hMSCs therapeutic use is still limited by the necessity of in vitro expansion.•Expansion of hMSCs in two-dimensional culture is discussed.•Key strengths and limitations of the most widely used bioreactors for generation of clinical grade hMSCs are summarized.•The challenges for further development of hMSCs manufacturing platforms and the ideal microcarrier for mass production of hMSCs for clinical translation are discussed. Human mesenchymal stem cells (hMSCs) are multipotent cells and an attractive therapeutic agent in regenerative medicine and intensive clinical research. Despite the great potential, the limitation that needs to be overcome is the necessity of ex vivo expansion because of insufficient number of hMSCs presented within adult organs and the high doses required for a transplantation. As a result, numerous research studies aim to provide novel expansion methods in order to achieve appropriate numbers of cells with preserved therapeutic quality. Bioreactor-based cell expansion provide high-level production of hMSCs in accordance with good manufacturing practice (GMP) and quality standards. This review summarizes current knowledge about the hMSCs manufacturing platforms with a main focus to the application of bioreactors for large-scale production of GMP-grade hMSCs.